Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 10/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23773258 | 0.92 | ATF4 (0.56) | ATF4ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL23773086 | 0.89 | ATF4 (0.56) | ATF4 | |
| SCHEMBL23773299 | 0.89 | ATF4 (0.56) | ATF4L3MBTL1 | |
| SCHEMBL23773097 | 0.85 | ATF4 (0.49) | ATF4MEN1KMT2ALMNAHTT | |
| SCHEMBL23773245 | 0.83 | ATF4 (0.47) | ATF4ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL23773243 | 0.83 | ATF4 (0.52) | ATF4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL21618336 | 0.83 | ATF4 (0.68) | ATF4ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL23773277 | 0.83 | ATF4 (0.46) | ATF4ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL21621072 | 0.83 | ATF4 (0.53) | ATF4MEN1KMT2AL3MBTL1LMNA | |
| SCHEMBL23773390 | 0.82 | ATF4 (0.58) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253528-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253528-A1 | CHEMICAL COMPOUNDS | ATF4, EIF2AK4, ATF1 | ATF4 1/4885ALDH1A1 3644/4885MEN1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.